methyl 1-(3,5-bis(trifluoromethyl)phenyl)cyclopropanecarboxylate | 334477-29-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 1-(3,5-bis(trifluoromethyl)phenyl)cyclopropanecarboxylate
• 英文别名: Methyl 1-[3,5-Bis(trifluoromethyl)phenyl]cyclopropanecarboxylate；methyl 1-[3,5-bis(trifluoromethyl)phenyl]cyclopropane-1-carboxylate
• CAS: 334477-29-1
• 化学式: C₁₃H₁₀F₆O₂
• 分子量: 312.212
• InChiKey: SXCNJIHQWVELBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  methyl 1-(3,5-bis(trifluoromethyl)phenyl)cyclopropanecarboxylate 在 lithium hydroxide 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以100%的产率得到1-[3,5-双(三氟甲基)苯基]环丙烷羧酸
  参考文献：
  名称：

  Synthesis and pharmacological characterization of constrained analogues of Vestipitant as in vitro potent and orally active NK1 receptor antagonists

  摘要：

  A focused exploration targeting conformationally restricted analogues of Vestipitant, resulted in the discovery of novel, in vitro potent NK1 antagonists. In particular, two of the compounds reported exhibited a good pharmacokinetic (PK) profile and produced anxiolytic-like effects in the gerbil foot tapping (GFT) in vivo model. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.078
• 作为产物：
  描述：

  methyl 2-(3,5-bis(trifluoromethyl)phenyl)acrylate 、 三甲基碘化亚砜 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以16%的产率得到methyl 1-(3,5-bis(trifluoromethyl)phenyl)cyclopropanecarboxylate
  参考文献：
  名称：

  Synthesis and pharmacological characterization of constrained analogues of Vestipitant as in vitro potent and orally active NK1 receptor antagonists

  摘要：

  A focused exploration targeting conformationally restricted analogues of Vestipitant, resulted in the discovery of novel, in vitro potent NK1 antagonists. In particular, two of the compounds reported exhibited a good pharmacokinetic (PK) profile and produced anxiolytic-like effects in the gerbil foot tapping (GFT) in vivo model. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.078

文献信息

• Cyclohexane derivatives and their use as therapeutic agents
  申请人：——

  公开号：US20030236250A1

  公开（公告）日：2003-12-25

  The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 13 , R 14 , R 15 , R 16 , R 17 , R 21a and R 21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia. 1

  本发明涉及式(I)的化合物，其中环A是苯环或吡啶环；X代表从以下式组成的选择性连接物：(a)、(b)、(c)、(d)和(e)；以及R1、R2、R3、R4、R5、R6、R7、R13、R14、R15、R16、R17、R21a和R21b如本文所定义。这些化合物特别适用于治疗或预防抑郁症、焦虑、疼痛、炎症、偏头痛、呕吐或带状疱疹后神经痛。
• Synthesis of Substituted Cyclopropanecarboxylates via Room Temperature Palladium-Catalyzed α-Arylation of Reformatsky Reagents
  作者：Stephen N. Greszler、Geoff T. Halvorsen、Eric A. Voight

  DOI：10.1021/acs.orglett.7b00707

  日期：2017.5.19

  The room temperature palladium-catalyzed cross-coupling of aromatic and heteroaromatic halides with Reformatsky reagents derived from 1-bromocyclopropanecarboxylates provides an exceptionally mild method for enolate α-arylation. The method is tolerant of a wide range of functionalities and dramatically shortens many of the existing routes to access widely used 1,1-disubstituted cyclopropanecarboxylate

  室温钯催化的芳香族和杂芳香族卤化物与衍生自1-溴环丙烷羧酸盐的Reformatsky试剂的交叉偶联为烯醇化α-芳基化提供了一种异常温和的方法。该方法具有广泛的功能性，并且大大缩短了许多现有的获得广泛使用的1,1-二取代的环丙烷羧酸酯衍生物的途径。
• Chemical compounds
  申请人：——

  公开号：US20030028021A1

  公开（公告）日：2003-02-06

  The invention relates to piperazine derivatives, to processes for their preparation, to pharmaceutical compositions containing them, and to their medical use. The novel compounds are antagonists of tachykinins, including substance P and other neurokinins.

  本发明涉及哌嗪衍生物、其制备方法、包含它们的制药组合物以及它们的医疗用途。这些新化合物是缓解速激肽素（包括物质P和其他神经激肽素）的拮抗剂。
• Chemical Compounds
  申请人：Alvaro Giuseppe

  公开号：US20080249108A1

  公开（公告）日：2008-10-09

  The invention relates to methods for the treatment of medical conditions comprising administering an effective amount of a compound of formula (I): wherein all variables are as defined herein.

  本发明涉及治疗医疗状况的方法，包括给予公式（I）化合物的有效量：其中所有变量在此定义。
• Nitrogen-containing heterocyclic compound and use of same
  申请人：Shirai Junya

  公开号：US08592454B2

  公开（公告）日：2013-11-26

  The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle; ring B is an aromatic ring optionally having substituent(s); ring D is an aromatic ring optionally having substituent(s); L is a group represented by the formula R2, R3, R4a and R4b are each independently a hydrogen atom, an optionally halogenated C1-6 alkyl group or an optionally halogenated C3-6 cycloalkyl group, or R2 and R3 are optionally bonded via an alkylene chain or an alkenylene chain, or R4a and R4b are optionally bonded via an alkylene chain or an alkenylene chain; R1 is a hydrogen atom or a substituent; m and n are each independently an integer of 0 to 5; m+n is an integer of 2 to 5; and is a single bond or double bond, or a salt thereof; and the like. The compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, digestive tract diseases, central neurological disease and the like.

  本发明涉及一种化合物，其表示为以下式子： 其中，环A是含氮杂环；环B是芳香环，可选地具有取代基；环D是芳香环，可选地具有取代基；L是以下式子表示的基团： 其中，R2、R3、R4a和R4b各自独立地是氢原子、可选卤代的C1-6烷基或可选卤代的C3-6环烷基，或者R2和R3通过烷基链或烯基链连接，或者R4a和R4b通过烷基链或烯基链连接；R1是氢原子或取代基；m和n各自独立地是0至5的整数；m+n是2至5的整数；是单键或双键，或其盐；等等。该化合物具有优良的缩氨酸受体拮抗作用，可用作预防或治疗各种疾病的药物，例如下尿路疾病、消化道疾病、中枢神经系统疾病等。